A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers
Launched by CHIRHOCLIN, INC. · Mar 15, 2010
Trial Information
Current as of October 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Documented or suspected diagnosis of chronic pancreatitis or suspected diagnosis of pancreatic cancer.
- • 2. Undergoing Endoscopic Procedure.
- • 3. Age ≥ 18 years.
- • 4. Willing and able to sign informed consent, meeting IRB guidelines.
- • 5. Willing and able to meet all study requirements and obligations.
- Exclusion Criteria:
- • 1. Ongoing, active pancreatitis at the time of the procedure.
- • 2. Known adverse reaction to secretin.
- • 3. Recent (within one month) use of medication that can potentially cause pancreatitis, such as metronidazole, tetracycline, sulfonamides.
- • 4. Use of anticholinergic medication within 7 days of study.
- • 5. Pregnant women, nursing mothers, or women of childbearing potential not employing appropriate contraception. Acceptable methods of birth control are: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive (started at least one month prior to Visit 1 and continuing for the duration of the trial), contraceptive patch, condoms with spermicide or abstinence.
- • 6. Any medical condition which in the judgment of the Principal Investigator makes participation of the patient in the study medically unwarranted.
- • 7. Known complete obstruction of the pancreatic duct.
- • 8. Patients who have received an investigational product/drug or device within 30 days prior to Visit 1.
About Chirhoclin, Inc.
Chirhoclin, Inc. is a clinical trial sponsor dedicated to advancing innovative therapies in the field of healthcare. With a focus on enhancing patient outcomes, the company specializes in conducting rigorous clinical studies that adhere to the highest ethical and regulatory standards. Leveraging a team of experienced professionals and state-of-the-art technology, Chirhoclin, Inc. collaborates with leading researchers and healthcare institutions to bring cutting-edge treatments from the laboratory to the clinic. Committed to scientific excellence and patient safety, Chirhoclin, Inc. aims to contribute significantly to the development of new medical solutions that address unmet clinical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Louis, Missouri, United States
Patients applied
Trial Officials
Frank Burton, M.D.
Principal Investigator
St. Louis University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials